First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).

被引：10
|
作者：
Hirsh, Vera
Yang, James Chih-Hsin
Tan, Eng-Huat
O'Byrne, Ken
Zhang, Li
Boyer, Michael J.
Mok, Tony
Lee, Ki Hyeong
Lu, Shun
Shi, Yuankai
Kim, Sang-We
Laskin, Janessa J.
Kim, Dong-Wan
Arvis, Catherine Dubos
Kolbeck, Karl
Schuler, Martin H.
Massey, Dan
Maerten, Angela
Paz-Ares, Luis
Park, Keunchil
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[4] Natl Canc Ctr, Singapore, Singapore
[5] Princess Alexandra Hosp, Brisbane, Qld, Australia
[6] Queensland Univ Technol, Brisbane, Qld, Australia
[7] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[8] Chris OBrien Lifehouse, Camperdown, NSW, Australia
[9] Chinese Univ Hong Kong, Dept Clin Oncol, Key Lab South China, Hong Kong, Peoples R China
[10] Chungbuk Natl Univ Hosp, Cheongju, North Chungcheo, South Korea
[11] Shanghai Chest Hosp, Shanghai, Peoples R China
[12] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[13] Peking Union Med Coll, Beijing, Peoples R China
[14] Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[15] Asan Med Ctr, Seoul, South Korea
[16] BC Canc Agcy, Vancouver, BC, Canada
[17] Seoul Natl Univ Hosp, Seoul, South Korea
[18] Ctr Francois Baclesse, Oncol, Caen, France
[19] Karolinska Univ Hosp, Stockholm, Sweden
[20] Univ Hosp Essen, Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[21] Boehringer Ingelheim Ltd UK, Bracknell, Berks, England
[22] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[23] Hosp Univ Doce Octubre, Madrid, Spain
[24] CNIO, Madrid, Spain
[25] Sungkyunkwan Univ, Canc Med Inst, Samsung Med Ctr, Sch Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9046
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9046
引用
收藏
页数：3
相关论文
共 41 条
  • [21] LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations
    Geater, Sarayut Lucien
    Zhou, Caicun
    Hu, Cheng-Ping
    Feng, Ji Feng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Shi, Jian Hua
    Lee, Kye Young
    Massey, Dan
    Lungershausen, Juliane
    Shi, Yang
    Zazulina, Victoria
    Wu, Yi Long
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
    Wehler, T.
    Wehler, B.
    Atmaca-Dirik, H.
    Schulz, C.
    Grohe, C.
    Topsch, J.
    Ehrlich, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
  • [23] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    Passaro, A.
    Yang, J. C.
    Ahn, M.
    Dickgreber, N. J.
    Halmos, B.
    Hirsh, V.
    Hochmair, M. J.
    Levy, B. P.
    de Marinis, F.
    Mok, T.
    O'Byrne, K.
    Okamoto, I.
    Schuler, M.
    Sebastian, M.
    Shah, R.
    Tan, E.
    Yamamoto, N.
    Maerten, A.
    Wind, S.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2015, 26 : 77 - 77
  • [24] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Dickgreber, Nicolas J.
    Halmos, Balazs
    Hirsh, Vera
    Hochmair, Maximilian J.
    Levy, Benjamin Philip
    De Marinis, Filippo
    Mok, Tony
    O'Byrne, Kenneth
    Okamoto, Isamu
    Schuler, Martin H.
    Sebastian, Martin
    Shah, Riyaz N. H.
    Tan, Eng-Huat
    Yamamoto, Nobuyuki
    Marten, Angela
    Massey, Dan
    Wind, Sven
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] LUX-Lung 7: A Phase lib, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
    Park, K.
    Tan, E. -H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J.
    Mok, T.
    Kim, M.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S117 - S118
  • [26] Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
    Park, K.
    Tan, E-H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T.
    Kim, M.
    Massey, D.
    Zazulina, V.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 161 - 162
  • [27] Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
    Yi-Long Wu
    Vera Hirsh
    Lecia V. Sequist
    Cheng-Ping Hu
    Jifeng Feng
    Shun Lu
    Yunchao Huang
    Martin Schuler
    Tony Mok
    Nobuyuki Yamamoto
    Kenneth O’Byrne
    Sarayut L. Geater
    Caicun Zhou
    Dan Massey
    Angela Märten
    Juliane Lungershausen
    James Chih-Hsin Yang
    The Patient - Patient-Centered Outcomes Research, 2018, 11 : 131 - 141
  • [28] Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
    Wu, Yi-Long
    Hirsh, Vera
    Sequist, Lecia V.
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Schuler, Martin
    Mok, Tony
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Geater, Sarayut L.
    Zhou, Caicun
    Massey, Dan
    Maerten, Angela
    Lungershausen, Juliane
    Yang, James Chih-Hsin
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 11 (01): : 131 - 141
  • [29] Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    Schuler, M.
    Yang, J.
    Sequist, L. V.
    Yamamoto, N.
    Zhou, C.
    O'Byrne, K.
    Hirsh, V.
    Mok, T.
    Shah, R.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S116 - S117
  • [30] Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR-Mutation Positive (EGFR M plus ) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A)
    Wu, Y.
    Geater, S. L.
    Mok, T.
    O'Byrne, K. J.
    Schuler, M. H.
    Sequist, L. V.
    Yang, J. C.
    Massey, D.
    O'Brien, D.
    Zazulina, V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S41 - S41
12345